To eliminate the undesirable edematogenic effect of the lutemizing hormone-releasing hormone (LH- Since the isolation and structural elucidation of hypothalamic luteinizing hormone-releasing hormone (LH-RH) more than 2000 analogs have been synthesized, in view of their expected medical applications (1). Chronic administration of potent LH-RH agonists leads to the inhibition of pituitary and gonadal functions (2-6). While repeated administration of LH-RH agonists is required to lower the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroids, similar effects can be obtained with single administration of LH-RH antagonists (7). Competitive antagonists of LH-RH were developed by multiple modification of the parent molecule, <Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-ProGly-NH2 (8) (9) (10) (11) (12) (13) (14) (<Glu, pyroglutamic acid). Agonist activity is reduced by substitution of aromatic D amino acids at positions 2 and 3, and receptor affinity is retained when there are replacements at residues 1 and 6, and in some analogs also in position 10. LH-RH antagonists are frequently character- , was reported to be 1/10th as potent as I in releasing histamine and showed no edematogenic effect in the rat at the doses tested (0.5-1.0 mg/kg) (14). Antagonist H, which induced edema at the challenge dose of 1.5 mg/kg, was also about 1/10th as potent in histamine release assays as the other hydrophilic antagonists studied (16).
Since the isolation and structural elucidation of hypothalamic luteinizing hormone-releasing hormone (LH-RH) more than 2000 analogs have been synthesized, in view of their expected medical applications (1) . Chronic administration of potent LH-RH agonists leads to the inhibition of pituitary and gonadal functions (2) (3) (4) (5) (6) . While repeated administration of LH-RH agonists is required to lower the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and sex steroids, similar effects can be obtained with single administration of LH-RH antagonists (7) . Competitive antagonists of LH-RH were developed by multiple modification of the parent molecule, <Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-ProGly-NH2 (8) (9) (10) (11) (12) (13) (14) (<Glu, pyroglutamic acid). Agonist activity is reduced by substitution of aromatic D amino acids at positions 2 and 3, and receptor affinity is retained when there are replacements at residues 1 and 6, and in some analogs also in position 10 (15, 16) . In addition, these analogs cause a dose-related whealing response (17) , increase histamine levels in rats (16) , and elicit histamine release from rat mast cells (18) . The anaphylactoid reactions to these antagonists are not invariably associated with their edematogenic potencies (16) , was reported to be 1/10th as potent as I in releasing histamine and showed no edematogenic effect in the rat at the doses tested (0.5-1.0 mg/kg) (14) . Antagonist H, which induced edema at the challenge dose of 1.5 mg/kg, was also about 1/10th as potent in histamine release assays as the other hydrophilic antagonists studied (16) .
In contrast to hydrophilic antagonists, hydrophobic antagonists having a neutral aromatic D amino acid at position 6, for instance [Ac-A3-Pro1,D-Phe(pF)2,D-Trp3,6]LH-RH (IV), did not exhibit edematogenic effects at a dose of 1.25 or 5.0 mg/kg (19) and were about 1/200th as potent as I in triggering the release of histamine (18) . Thus, it seems likely that a structural combination of the basic D-Arg6 residue and a cluster of three aromatic D amino acids at the N terminus confers the anaphylactoid side reactions on LH-RH antagonists (19) . Consequently, it could be conjectured that the introduction of a neutral hydrophilic residue into position 6 (20) . Benzhydrylamine resin (0.5-1.0 mmol/g) was used as starting material. Amino acids were coupled as their Na-t-butoxycarbonyl (Boc) derivatives, and side-chain functional groups of the Na-Boc-amino acids were protected as follows: serine, 0-benzyl; tyrosine, 0-2,6-dichlorobenzyl; D-ornithine, N8-benzyloxycarbonyl; D-lysine, Ne-2-chlorobenzyloxycarbonyl; arginine, NG-p-toluenesulfonyl. The Amino Acid Analysis. Amino acid analyses were performed in a Beckman 6300 amino acid analyzer, on samples that were hydrolyzed at 110°C for 20 hr in evacuated sealed tubes containing 4 M methanesulfonic acid and 0.2% 3-(2-aminoethyl)indole.
Detection of LH-RH Antagonist Activity in Vitro. LH-RH antagonist activity of the peptides was assayed by using a superfused rat pituitary cell system (22) . Each peptide was perfused through the cells for 9 min (3-ml perfusate) at 3-100 nM. Immediately after that, a mixture containing the same concentration of the peptide and 1 nM LH-RH was administered for 3 min. This was followed by four consecutive infusions of 1 nM LH-RH for 3 min (1 ml) at 30-min intervals (30, 60, 90 , and 120 min). LH content of the 1-ml fractions collected was determined by radioimmunoassay (RIA).
In Vivo Antiovulatory Assay. This assay was carried out in 4-day-cycling rats as described by Corbin and Beattie (23) .
Anaphylactoid Activities. Assays for the edematogenic activity in vivo, cutaneous anaphylactoid reaction in vivo, and histamine-releasing potency in vitro were carried out essentially as described by Morgan et al. (16) .
Edematogenic Effect. Six groups of 6-10 rats were injected s.c. once a day on 2 consecutive days with the antagonists (1.5 mg/kg dissolved in 0.2 ml of sterile deionized water). Control rats were injected with diluent. The rats were observed during 8 hr on each day. The reactions of rats were classified as follows: no apparent reaction (NR), partial responders (PR; edema of nasal and paranasal area), and full responders (FR; facial edema with edematous extremities).
Cutaneous Anaphylactoid Reactions. Rats were anesthetized with pentobarbital (6 mg/100 g of body weight). One milliliter of 0.5% Evans blue dye was injected into the jugular vein. The antagonists were diluted with saline to concentrations of 0.5, 1, 5, and 10 1Lg/ml. A standard volume (0.05 ml) of these solutions was injected intradermally. Each rat was injected with a negative control (0.05 ml of saline). Rats were decapitated 20 min after the injection and the reactions were read by measuring the blue lesions in reflected skin.
Histamine Release in Vitro. Rat peritoneal exudate cells were harvested and histamine release from mast cells was triggered by antagonists as described (16) . Histamine levels were determined with a histamine RIA kit (NMS Pharmaceuticals, Newport Beach, CA). The concentration of each antagonist that released 50o of total mast cell histamine (HRD50) was determined. The peptides Al, referred to as ureido antagonists, were prepared by carbamoylation with potassium cyanate and N-ethylisocyanate, respectively, of the corresponding DOrn6-and D-Lys6-containing analogs having the general formula A2. The precursor peptides, A2, were made by standard solid-phase methods (20) . After purification by preparative HPLC, the purity of isolated peptides was calculated to be greater than 95% on the basis of absorbance data obtained on HPLC in two systems. Amino acid analyses of the pure products showed the expected amino acid compositions. The effects of D-ureidoalkylamino acid residues on overall hydrophobicity or hydrophilicity of a peptide as compared to the related basic amino acids, such as D-Om7, D-Lys, and D-Arg, were estimated by HPLC. Compounds Al, their D-Orn6/D-Lys6 analogs, compounds A2, and the D-Arg6-containing antagonist II and its D-Nal(2) analog (VI) were analyzed by HPLC under isocratic conditions using 0.03 M ammonium acetate in 40% (vol/vol) aqueous acetonitrile as eluent at pH 7.2 (24, 25) . The capacity factor k' was used as a measure of the overall hydrophobicity of the analogs. The analogs are shown in Table 1 in order of increasing k' within the two series of peptides containing D-Phe(pCI)1 and DNal(2)', respectively.
The peptides were tested for their ability to inhibit LH-RH-mediated LH release from perfused rat pituitary cells in vitro. Every antagonist tested at 10 and 100 nM completely blocked LH-RH response. Every peptide also caused a significant decrease in response to LH-RH even at 3 nM ( Table 2 ). The duration of the inhibitory effect of the antagonists after four consecutive exposures to LH-RH at 30-min intervals was variable. Antagonist activity of some analogs decreased rapidly. However, other analogs, when tested at 3 nM, showed the strongest blocking activity 60 or even 120 min after their infusion was stopped (Table 2) .
Proc. Natl. Acad. Sci. USA 85 (1988) In vivo antiovulatory activity of peptides 1-8 as compared to their D-Arg6-containing parent compound, II, was determined by injecting the peptides s.c. in aqueous solution into rats at noon on the day of proestrus. Table 3 shows the results as a percentage of the inhibition of ovulation and as the ratio of rats that did not ovulate to the total number of rats treated. Parent compound II and its D-Hci6 analog (3) were about equipotent, while the D-Cit6 congener (1) showed somewhat less potency. Introduction of D-Nal(2) into position 1 resulted in analogs with enhanced activities (2 and 4) . However, analogs 5-8 with D-Cit(Et)6 or D-Hci(Et)6 showed lower potencies than the D-Cit6/D-Hci6-containing peptides or were inactive at 3 ,ug per rat.
To assess the duration of inhibitory action of the D-Cit/DHci6 analogs on LH secretion, as compared to the antagonist with D-Arg6, analogs 1-4 and II were injected s.c. in 40% (vol/vol) propylene glycol in saline to ovariectomized female rats and blood samples were drawn at various time intervals. Fig. 1 shows that antagonists II and 1 induced a significant (P < 0.01) inhibition of LH secretions for 23 hr at doses of 100 ,ug. The suppression after the high dose of antagonist II was also significant at 30 hr. Analogs 24 suppressed LH for 47 hr at both doses (P < 0.05).
Anaphylactoid activities of the D-Cit/D-Hci6 antagonists 14 and two reference compounds-the D-Arg6 antagonist II and the Arg5 analog of 4, 4a-as measured in three assays, are shown in Table 4 . In accord with previous findings (16) , the D-Arg6 antagonist II proved to be highly edematogenic at a dose of 1.5 mg/kg. Seven of 10 rats reacted 60-120 min after injection on day 1, and all 10 rats showed edema on day 2. Edema formation started 45 min after the injection. The peak reaction occurred between 60 and 90 min, was present during the 8 hr of observation, but subsided completely 24 hr after the injection. No edematous reactions could be observed with the D-Cit/D-Hci6 antagonists. Only antagonist 3 produced a very light edema in 1 of 9 rats, 3 hr after injection on day 2. Light edema of the face could also be observed in 2 of 6 rats treated with 4a. In the cutaneous anaphylaxis assay, all antagonists elicited skin reactions in a dosedependent fashion, and all analogs induced histamine release The intensity and duration of the LH-RH antagonistic activity of the analogs were examined in the superfusion assay. The intensity of the instant antagonistic activity was determined by exposure to 1 nM LH-RH for 3 min in the presence of the analog after incubation with it for 9 min. In every case a complete inhibition of response to LH-RH was found at 10 and 100 nM. Antagonists II, 2, 3, 5, and 6 also canceled LH-RH responses at 5 nM ( Table 2) .
The dynamics of the antagonistic activity were analyzed by exposing cells preincubated with the antagonists to 1 nM The cells were first exposed to the analogs at 3, 5, 10, or 100 nM for 9 min. At that time 1 nM LH-RH was also given for 3 min together with the analogs (0-min response). LH-RH was also administered 30, 60, 90, and 120 min later. At 100 nM all antagonists gave 100%o inhibition (data not shown). LH-RH, four times for 3 min at 30-min intervals. The time needed for the recovery of the normal LH-RH response varied for different peptides. At the highest doses (10 and 100 nM) only the duration of the inhibitory effect could be determined. However, at the 3 nM dose, more subtle differences between the analogs could be detected. Some peptides showed the highest inhibitory activity at 0 min (Table 2 ) and the normal LH-RH response continued to recover after that. Other analogs, II, 2, 3, 4, and 8, first exhibited only a moderate antagonistic activity and showed the strongest inhibitory effect 30, 60, or even 90 min after the preincubation had been stopped. These findings suggest that the initial association rates for LH-RH and some antagonists are different. In a 3-min reaction, LH-RH may bind to its receptor much faster than some antagonists. Binding of antagonists to sites that have relatively high affinity (or avidity) for these hydrophobic compounds but that cannot mediate gonadotropin release also takes place. In time, the dormant portion of antagonists residing at binding sites not concerned with the release of LH can migrate to the receptor site. This event results in a prolonged blockade of action of LH-RH and an apparent increase of antagonist potency. These results relate to the early events of receptor-peptide interaction and are consistent with reports by Perrin et al. (27) . Table 3 nists showed some anaphylactoid activity in the two other assays. Thus, they induced skin lesions following intradermal injection, although less intense than analog II when compared at 1-and 0.5-,ug doses. They also elicited histamine release but with intensities 1/2 to 1/3.5 the intensity of II, which is a relatively weak histamine releaser, about 1/10 as strong as the related edematogenic antagonists I (14) and VI (16) . These data provide further evidence that the activity of antagonists in the last two tests cannot predict their anaphylactoid activity in general. The most relevant of these side effects, edema, should be determined directly and at the doses of 1.25-1.5 mg/kg as suggested previously (15, 16) . In view of favorable clinical results with LH-RH agonists in the treatment of various tumors, the development of LH-RH antagonists is indicated (6, 7, 29, 30) . The advantage of the antagonists is based on the fact that they inhibit LH and FSH and, thus, sex steroids from the start of administration (30) . The use of antagonists would avoid the transient stimulation that occurs initially in response to LH-RH agonists and prevent the temporary clinical "flare-up" of the disease. LH-RH antagonists could be useful for contraception, the treatment of hormone-dependent tumors, and prevention of gonadal damage caused by radiation and chemotherapy (7, 30) .
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